Why the study?
Atorvastatin has suboptimal efficacy in COPD combined with atherosclerosis, and whether Tongxinluo enhances its therapeutic effect by protecting pulmonary microvascular endothelial barrier function is unknown.
Does Tongxinluo combined with atorvastatin improve atherosclerosis and pulmonary microvascular barrier function in a model of COPD with atherosclerosis compared to atorvastatin alone?
Does Tongxinluo combined with atorvastatin improve atherosclerosis and pulmonary microvascular barrier function in a model of COPD with atherosclerosis compared to atorvastatin alone?
Tongxinluo enhances the anti-atherosclerotic effect of atorvastatin in a preclinical model of COPD with atherosclerosis by protecting pulmonary microvascular barrier function.
Answers are grounded in this paper and cite their sources.
May support adjunctive atorvastatin in COPD-AS; leaves open whether microvascular barrier effects translate to clinical outcomes.
Background: Atherosclerosis (AS) is a common comorbidity of chronic obstructive pulmonary disease (COPD) and the main cause of death in patients with COPD. Systemic inflammation is a significant mechanism of COPD with AS. The dysfunction of pulmonary microvascular barrier is involved in the formation of chronic inflammation in COPD, and its functional disruption will induce systemic inflammation. Atorvastatin (Ato) is a common medicine for the treatment of AS; however, the effect is not ideal for COPD combined with AS. Tongxinluo (TXL) improves the function of vascular endothelial cells. This study aims to prove that the impairment of pulmonary microvascular barrier function participated in the process of COPD aggravating AS and investigated whether TXL enhances the therapeutic effect of Ato on COPD with AS by protecting the pulmonary microvascular endothelial barrier function. Methods: In vivo, the COPD with AS model of ApoE-/- mice was established by cigarette smoke combined with a high-fat diet. The animals were administered TXL (1.5 g/kg/day), Ato (10 mg/kg/day), and TXL+Ato once a day for 20 weeks. Then, lung function, lung microvascular permeability, lung inflammation, systemic inflammation, serum lipid level, atheromatous plaque formation, and the biomarker of endothelial damage were measured. In vitro, human pulmonary microvascular endothelial cells (HPMECs) were pretreated with TXL for 6 h and incubated with cigarette smoke extract (CSE) for 24 h to establish a model of CSE-induced pulmonary microvascular barrier dysfunction. The permeability of the endothelial monolayer, inflammatory cytokines, endothelial damage biomarkers, tight junction proteins were determined. Results: Cigarette smoking significantly exacerbated, which induced by high fat diet, the pulmonary function decline, pulmonary microvascular endothelial barrier dysfunction, pulmonary and systemic inflammation, and atherosclerotic plaque. These changes were reversed by TXL-Ato combination; the combination therapeutic effect was better than that of Ato alone. In addition, TXL protected the function of HPMEC barrier and inhibited the inflammation in CSE-induced HPMECs. Conclusions: COPD aggravates AS, the mechanism may be the destruction of pulmonary microvascular barrier function and thus lung inflammation triggers systemic inflammation. In treating COPD with AS, TXL enhances the anti-AS effect of Ato protecting the pulmonary microvascular barrier.
No takes yet. Share an insight, caveat, or question.
Kuang et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: